HealthDay News — Published papers addressing the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies have a high risk for bias, according to a study published online August 4 in the Journal of Investigative Dermatology.
Stephano Piaserico, MD, PhD, from the University of Padua in Italy, and colleagues analyzed the quality of papers addressing the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies. The quality of 25 published studies was estimated using the Newcastle-Ottawa Scale (NOS).
The researchers found that the median NOS score was 47 and 44% for psoriasis and psoriatic arthritis, respectively, indicating a high risk for bias. Of the psoriasis and psoriatic arthritis studies, 37 and 44%, respectively, included patients with suspected COVID-19 without a positive swab. None of the studies provided a calculation of formal sample size.
“Our study is not intended as a criticism to the authors or the journals that published their research,” Piaserico said in a statement. “Rather, it is a reminder to be careful when reading new COVID-19 papers. During a pandemic, health care providers should be more cautious when incorporating evidence from new studies into personal decision making.”
Several authors disclosed financial ties to the pharmaceutical industry.